Global Hematology Partnering 2010-2017: Deal trends, players and financials

Publisher Name :
Date: 01-Apr-2017
No. of pages: 600
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

The Global Hematology Partnering 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the hematology partnering deals and agreements entered into by the worlds leading healthcare companies

Global Hematology Partnering 2010 to 2017 provides the full collection of Hematology disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Hematology partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Hematology partnering agreement structure

Hematology partnering contract documents

Top Hematology deals by value

Most active Hematology dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Hematology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Hematology deals.

The report presents financial deal terms values for Hematology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Hematology dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Hematology dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Hematology deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Hematology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Hematology deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Hematology partnering deals by specific Hematology target announced since 2010. The chapter is organized by specific Hematology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Hematology partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Hematology partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Hematology technologies and products.

Report scope

Global Hematology Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Hematology trends and structure of deals entered into by leading companies worldwide.

Global Hematology Partnering 2010 to 2017 includes:

Trends in Hematology dealmaking in the biopharma industry since 2010

Analysis of Hematology deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Hematology deal contract documents

Comprehensive access to over 3500 Hematology deal records

The leading Hematology deals by value since 2010

Most active Hematology dealmakers since 2010

The report includes deals for the following indications: Agranulocytosis, Anemia, Haemolytic, Iron deficiency, Blood substitute, Disseminated intravascular coagulation (DIC), Hemophilia, Immune thrombocytopenic purpura, Neutropenia, Polycythemia, Thalassemia, Thrombocytopenia, Vitamin K Deficiency, Von-Willebrand disease, plus other hematological indications.

In Global Hematology Partnering 2010 to 2017, available deals and contracts are listed by:

Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Hematology Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 1,000 hematology deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are the sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Hematology Partnering 2010 to 2017 provides the reader with the following key benefits:

In-depth understanding of Hematology deal trends since 2010

Access Hematology deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Hematology partner companies

Comprehensive access to over 750 links to actual Hematology deals entered into by the world's biopharma companies

Indepth review of Hematology deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Hematology opportunities

Uncover companies actively partnering Hematology opportunities

Global Hematology Partnering 2010-2017: Deal trends, players and financials

Table of Contents
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Hematology dealmaking
2.1. Introduction
2.2. Hematology partnering over the years
2.3. Hematology partnering by deal type
2.4. Hematology partnering by industry sector
2.5. Hematology partnering by stage of development
2.6. Hematology partnering by technology type
2.7. Hematology partnering by therapeutic indication

Chapter 3 -Financial deal terms for Hematology partnering
3.1. Introduction
3.2. Disclosed financials terms for Hematology partnering
3.3. Hematology partnering headline values
3.4. Hematology deal upfront payments
3.5. Hematology deal milestone payments
3.6. Hematology royalty rates

Chapter 4 - Leading Hematology deals and dealmakers
4.1. Introduction
4.2. Most active in Hematology partnering
4.3. List of most active dealmakers in Hematology
4.4. Top Hematology deals by value

Chapter 5 - Hematology contract document directory
5.1. Introduction
5.2. Hematology partnering deals where contract document available

Chapter 6 - Hematology dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Hematology therapeutic target

Appendices

Appendix 1 - Directory of Hematology deals by company A-Z 2010 to 2017
Appendix 2 - Directory of Hematology deals by deal type 2010 to 2017
Appendix 3 - Directory of Hematology deals by stage of development 2010 to 2017
Appendix 4 - Directory of Hematology deals by technology type 2010 to 2017
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Table of figures
Figure 1: Hematology partnering since 2010
Figure 2: Hematology partnering by deal type since 2010
Figure 3: Hematology partnering by industry sector since 2010
Figure 4: Hematology partnering by stage of development since 2010
Figure 5: Hematology partnering by technology type since 2010
Figure 6: Hematology partnering by indication since 2010
Figure 7: Hematology deals with a headline value
Figure 8: Hematology deals with upfront payment values
Figure 9: Hematology deals with milestone payment
Figure 10: Hematology deals with royalty rates
Figure 11: Active Hematology dealmaking activity- 2010 to 2017
Figure 12: Top Hematology deals by value since 2010
  • United States Injectable Anticoagulants Market Report 2017
    Published: 21-Jul-2017        Price: US 3800 Onwards        Pages: 102
    In this report, the United States Injectable Anticoagulants market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growt......
  • Europe Anticoagulants Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 21-Jul-2017        Price: US 4480 Onwards        Pages: 115
    Anticoagulants, commonly referred to as blood thinners, are substances that prevent or reduce coagulation of blood, prolonging the clotting time. Some of them occur naturally in blood-eating animals such as leeches and mosquitoes, where they help keep the bite area unclotted long enough for the animal to obtain some blood. As a class of medications, anticoagulants are used in therapy for thrombotic disorders. Oral anticoagulants (OACs) are taken by many people in pill or tablet form, and various......
  • Europe Injectable Anticoagulants Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 21-Jul-2017        Price: US 4480 Onwards        Pages: 122
    "The injectable anticoagulants include low molecular weight heparin (LMWH) agents (dalteparin [Fragmin?], enoxaparin [Lovenox?]) and factor Xa inhibitors (fondaparinux [Arixtra?]). In general, the injectable anticoagulants are Food and Drug Administration (FDA)-approved for prophylaxis and/or treatment of venous thromboembolism." Scope of the Report: This report focuses on the Injectable Anticoagulants in Europe market, especially in Germany, UK, Fran......
  • Global Intravenous Immunoglobulin (IVIg) Sales Market Report 2017
    Published: 20-Jul-2017        Price: US 4000 Onwards        Pages: 112
    In this report, the global Intravenous Immunoglobulin (IVIg) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Intravenous Immunoglobulin (IVIg) for these regions, from 2012 to 2022 (forecast), covering - United States - China......
  • EMEA (Europe, Middle East and Africa) Thrombin (Human) Market Report 2017
    Published: 18-Jul-2017        Price: US 4000 Onwards        Pages: 119
    In this report, the EMEA Thrombin (Human) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Thrombin (Human) for these regions, from 2012 to 2022 (forecast) - Europe: Germany, France, UK, Russia, Italy and Benelux;......
  • Global Intravenous Immunoglobulin (IVIg) Market Research Report 2017
    Published: 17-Jul-2017        Price: US 2900 Onwards        Pages: 116
    In this report, the global Intravenous Immunoglobulin (IVIg) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Intravenous Immunoglobulin (IVIg) in these regions, from 2012 to 2022 (forecast), covering - North America ......
  • Hematology Drugs Market Global Report 2017 Including: Blood Products, Anemia And Other Blood Disorder Drugs Covering: Baxalta, Bayer AG, Novo Nordisk, Pfizer Inc., and Biogen Idec
    Published: 17-Jul-2017        Price: US 4000 Onwards        Pages: 125
    Increase in number of Hematology disease drug approvals from the regulatory bodies such as FDA in the US and EMA in EU is an emerging trend in the market. For instance, in June 2017, Novo Nordisk received FDA approval for its Rebinyn (Coagulation Factor IX (Recombinant), GlycoPEGylated) that is used in the treatment of hemophilia B. The Hematology Drugs Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the ......
  • United States Thrombin (Human) Market Report 2017
    Published: 11-Jul-2017        Price: US 3800 Onwards        Pages: 105
    In this report, the United States Thrombin (Human) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of......
  • Thromboembolism - Pipeline Review, H2 2017
    Published: 11-Jul-2017        Price: US 2000 Onwards        Pages: 95
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thromboembolism - Pipeline Review, H2 2017, provides an overview of the Thromboembolism (Cardiovascular) pipeline landscape.When a blood clot (thrombus) breaks and travels in the blood, this is called a thromboembolism. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the chest wall or leg. Risk factors include hypertension, diabetes mellitus, cigarette smoking,......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs